Health Secretary Wes Streeting announces ‘indefinite’ ban on puberty blockers for children
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it’s investigating the financials of Elon Musk’s pro-Trump PAC or producing our latest documentary, ‘The A Word’, which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.
Puberty blockers for under-18s with gender dysphoria will be banned indefinitely in the UK due to the “unacceptable safety risk”, the government has announced.
Health and social care secretary, Wes Streeting, said there is a need to “act with caution” and “follow the expert advice” in caring for this “vulnerable group of young people”.
Mr Streeting announced an indefinite ban on the prescription of puberty blockers to children after the Commission on Human Medicines found there is “an unacceptable safety risk in the continued prescription of puberty blockers to children.”
A review by the body found children were prescribed the medication having just completed an online questionnaire and having had just one Zoom call.
The health secretary said any breach of the order would be a criminal offence.
In a statement to MPs in the House of Commons, Mr Streeting said: “I asked the Commission on Human Medicines to look at the current environment for prescribing puberty blockers, and we launched a targeted consultation.
“After thoroughly examining all the available evidence, they have concluded that prescribing puberty blockers to children for the purposes of gender dysphoria in the current prescribing environment represents, and I quote, ‘an unacceptable safety risk’. Of particular concern to the Commission was whether these children and their families were provided with enough time and information to give their full and informed consent.”
He added: “On the basis of their findings, I am acting on the Commission’s advice to put an indefinite order in place to restrict the sale or supply of puberty blockers through a prescription issued by either a private UK prescriber or a prescriber registered outside the UK for under-18s.”
“We are working with NHS England to open new gender identity services, so people can access holistic health and well-being support they need.
“We are setting up a clinical trial into the use of puberty blockers next year, to establish a clear evidence base for the use of this medicine.”
The NHS announced in March that children would no longer be prescribed puberty blockers at gender identity clinics, with the then-Conservative government saying this would help ensure care is based on evidence and is in the “best interests of the child”.
The following month, the Cass Review concluded that the quality of studies claiming to show beneficial effects for children and young people with gender dysphoria was “poor”.
In May, a ban on puberty blockers was introduced by the then government with emergency legislation, preventing the prescription of the medication from European or private prescribers and restricting NHS provision to within clinical trials.
A trial is due to start next into the impact and effectiveness of puberty blockers on children. On Monday reports by the BBC revealed scientists are facing various ethical concerns over the trial.
Dr Cass – now Baroness Cass – said at the time of her final report into children’s gender care that a single Dutch study, “suggesting puberty blockers may improve psychological wellbeing for a narrowly defined group of children with gender incongruence”, had formed the basis for their use to “spread at pace to other countries”.
“I support the Government’s decision to continue restrictions on the dispensing of puberty blockers for gender dysphoria outside the NHS where these essential safeguards are not being provided.”
